Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines

Roche has entered a drug discovery agreement with Defand Therapeutics, a Chinese biotechnology company, according to STAT News. The collaboration centers on molecular glue medicines, a class of drugs designed to force proximity between proteins that would not otherwise interact, with the aim of triggering the degradation of disease-causing targets.

STAT News reported the deal on October 8, confirming the two companies as parties to the agreement and identifying its focus as molecular glue drug discovery. The published summary does not specify financial terms, the number or identity of targets involved, or a timeline for the partnership’s work.

The report does not detail Defand Therapeutics’ prior work in this area, nor does it describe Roche’s broader portfolio beyond this specific agreement. No statement is given from either company’s executives in the available material, and no additional context on deal structure, such as upfront payments or milestone arrangements, is included in the source.

Molecular glues function differently from more established targeted protein degradation approaches by exploiting natural binding surfaces to bring together a target protein and a cellular disposal mechanism. The STAT News summary frames the Roche-Defand agreement specifically within this mechanism, without elaborating further on the scientific rationale or prior data supporting the approach.

This bulletin reflects only what the cited reporting confirms.